tetano
Editor, Senior Moderator
Virol J
. 2021 Jan 7;18(1):12.
doi: 10.1186/s12985-020-01478-9.
Higher expression of monocyte chemotactic protein 1 in mild COVID-19 patients might be correlated with inhibition of Type I IFN signaling
Xueyan Xi[SUP] 1 2 3 [/SUP], Yang Guo[SUP] 4 5 [/SUP], Min Zhu[SUP] 4 [/SUP], Yuhui Wei[SUP] 6 [/SUP], Gang Li[SUP] 7 [/SUP], Boyu Du[SUP] 4 [/SUP], Yunfu Wang[SUP] 8 9 [/SUP]
Affiliations
Abstract
Background: Chemokine levels in severe coronavirus disease 2019 (COVID-19) patients have been shown to be markedly elevated. But the role of chemokines in mild COVID-19 has not yet been established. According to the epidemiological statistics, most of the COVID-19 cases in Shiyan City, China, have been mild. The purpose of this study was to evaluate the level of chemokines in mild COVID-19 patients and explore the correlation between chemokines and host immune response.
Methods: In this study, we used an enzyme-linked immunosorbent assay to detect serum levels of chemokines in COVID-19 patients in Shiyan City. Expression of chemokine receptors and of other signaling molecules was measured by real-time polymerase chain reaction.
Results: We first demonstrated that COVID-19 patients, both sever and mild cases, are characterized by higher level of chemokines. Specifically, monocyte chemotactic protein 1 (MCP-1) is expressed at higher levels both in severe and mild cases of COVID-19. The receptor of MCP-1, C-C chemokine receptor type 2, was expressed at higher levels in mild COVID-19 patients. Finally, we observed a significant negative correlation between expression levels of interferon (IFN) regulatory factor 3 (IRF3) and serum levels of MCP-1 in mild COVID-19 patients.
Conclusion: Higher expression of MCP-1 in mild COVID-19 patients might be correlated with inhibition of IFN signaling. The finding adds to our understanding of the immunopathological mechanisms of severe acute respiratory syndrome coronavirus 2 infection and provides potential therapeutic targets and strategies.
Keywords: COVID-19; Chemokines; IFN signaling; MCP-1; Mild.
. 2021 Jan 7;18(1):12.
doi: 10.1186/s12985-020-01478-9.
Higher expression of monocyte chemotactic protein 1 in mild COVID-19 patients might be correlated with inhibition of Type I IFN signaling
Xueyan Xi[SUP] 1 2 3 [/SUP], Yang Guo[SUP] 4 5 [/SUP], Min Zhu[SUP] 4 [/SUP], Yuhui Wei[SUP] 6 [/SUP], Gang Li[SUP] 7 [/SUP], Boyu Du[SUP] 4 [/SUP], Yunfu Wang[SUP] 8 9 [/SUP]
Affiliations
- PMID: 33413449
- DOI: 10.1186/s12985-020-01478-9
Abstract
Background: Chemokine levels in severe coronavirus disease 2019 (COVID-19) patients have been shown to be markedly elevated. But the role of chemokines in mild COVID-19 has not yet been established. According to the epidemiological statistics, most of the COVID-19 cases in Shiyan City, China, have been mild. The purpose of this study was to evaluate the level of chemokines in mild COVID-19 patients and explore the correlation between chemokines and host immune response.
Methods: In this study, we used an enzyme-linked immunosorbent assay to detect serum levels of chemokines in COVID-19 patients in Shiyan City. Expression of chemokine receptors and of other signaling molecules was measured by real-time polymerase chain reaction.
Results: We first demonstrated that COVID-19 patients, both sever and mild cases, are characterized by higher level of chemokines. Specifically, monocyte chemotactic protein 1 (MCP-1) is expressed at higher levels both in severe and mild cases of COVID-19. The receptor of MCP-1, C-C chemokine receptor type 2, was expressed at higher levels in mild COVID-19 patients. Finally, we observed a significant negative correlation between expression levels of interferon (IFN) regulatory factor 3 (IRF3) and serum levels of MCP-1 in mild COVID-19 patients.
Conclusion: Higher expression of MCP-1 in mild COVID-19 patients might be correlated with inhibition of IFN signaling. The finding adds to our understanding of the immunopathological mechanisms of severe acute respiratory syndrome coronavirus 2 infection and provides potential therapeutic targets and strategies.
Keywords: COVID-19; Chemokines; IFN signaling; MCP-1; Mild.